Corona Remedies Ltd IPO

Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.

Demonstrated capabilities of building a diversified portfolio, including engine brands, in our targeted therapy areas.

Pan-India sales network and marketing strategy focused on the middle of the pyramid target market.

Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.

Qualified, experienced and entrepreneurial management team supported by marquee investors.

The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.

Our 27 engine brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our engine brands could have an adverse effect on our business, results of operations, financial condition and cash flows.

We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.

Further increase our market share within the domestic Indian pharmaceutical market.

Grow our product portfolio with a focus on long product life cycles and progression.

Expand into other therapeutic areas with significant growth potential and deepen our presence in existing therapeutic areas.

Execute strategic acquisitions and establish in-licensing agreements.

Expand our sales in select overseas markets with a focused approach.